Important Information for Investors of Geron Corporation: Class Action Lawsuit and Deadline Reminder
New York, NY – March 28, 2025
Investors who purchased the securities of Geron Corporation (NASDAQ: GERN) between February 28, 2024, and February 25, 2025, are reminded that they have until May 12, 2025, to apply to the Court for appointment as lead plaintiff in a class action lawsuit. The lawsuit alleges that Geron Corporation and certain of its top executives violated the Securities Exchange Act of 1934.
Background of the Case
The complaint alleges that Geron Corporation made false and misleading statements and failed to disclose material information in violation of the Securities Exchange Act of 1934. Specifically, the complaint alleges that the defendants made false and misleading statements regarding the commercial prospects of Geron’s telomerase inhibitor imetelstat and its potential to treat myelofibrosis and other hematologic diseases.
Impact on Individual Investors
If you purchased Geron Corporation securities during the Class Period, you may be entitled to compensation. The lead plaintiff will act on behalf of all other class members in the lawsuit. If you wish to serve as lead plaintiff, you must apply to the Court by May 12, 2025. If you wish to remain a class member, no action is required.
Impact on the World
The outcome of this lawsuit could have significant implications for the biotech industry as a whole. It could set a precedent for how securities fraud cases involving biotech companies are handled in the future. Additionally, if the allegations are proven true, it could damage Geron Corporation’s reputation and potentially lead to regulatory action against the company.
Conclusion
If you purchased Geron Corporation securities between February 28, 2024, and February 25, 2025, and believe that you may be affected by this lawsuit, it is important that you take action before the May 12, 2025, lead plaintiff deadline. You may be entitled to compensation, and the lead plaintiff will act on behalf of all other class members. If you wish to serve as lead plaintiff, you must apply to the Court by May 12, 2025. If you wish to remain a class member, no action is required.
It is important to note that investing in securities involves risks, and there is always the potential for loss. It is crucial to do thorough research and consult with a financial advisor before making any investment decisions. This information is not intended to be legal, tax, or investment advice.
- If you purchased Geron Corporation securities between February 28, 2024, and February 25, 2025, you may be entitled to compensation.
- The lead plaintiff deadline is May 12, 2025.
- If you wish to serve as lead plaintiff, you must apply to the Court by May 12, 2025.
- The outcome of this lawsuit could have significant implications for the biotech industry.
- It is important to do thorough research and consult with a financial advisor before making any investment decisions.
